Compare Wendys Co (WEN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs Zimmer Biomet Holdings Inc — how do they compare? Wendys Co trades at $7.56 (market cap $1.44B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 12.5× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| WEN | ZBH | |
|---|---|---|
Market Cap | $1.44B | $18.05B |
Sector | Consumer Cyclical | Health |
52-Week High | $9.89 | $104.26 |
52-Week Low | $6.17 | $79.58 |
Enterprise Value | $5.17B | $25.11B |
Dividend Yield | 3.71% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's (WEN) trades at $7.61, down 5.23% on the day, reflecting bearish technical signals and negative sentiment following the collapse of Trian's potential take-private bid. The stock shows a low P/E of 11.54 and P/S of 0.66, indicating potential undervaluation, but faces declining net income margins and high debt levels. Recent earnings have consistently beaten expectations, yet U.S. traffic fell 12.5% in 2026, highlighting operational challenges under new CEO Bob Wright's turnaround plan.
The outlook is cautious; while valuation metrics appear attractive and analyst consensus targets $8.13, near-term risks from weak sales, high leverage, and failed M&A speculation outweigh opportunities. Investors should monitor execution of the five-point reset strategy for traffic recovery, but competitive pressures and inconsistent cash flow generation pose significant headwinds for shareholder returns.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
